Aspirin, a widely used antiplatelet agent, has been a cornerstone in the prevention and management of cardiovascular diseases for decades. Its primary mechanism involves the irreversible inhibition of cyclooxygenase-1 (COX-1), leading to decreased thromboxane A2 production, thus reducing platelet aggregation. This pharmacologic effect makes aspirin particularly valuable in reducing th... https://www.cardiologymedjournal.com/jccm/about